Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products. It offers enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; naloxone for opioid overdose; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone909-980-9484
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$294.67 million
Profitability
Miscellaneous
Employees2,078
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Amphastar Pharmaceuticals (NASDAQ:AMPH) Frequently Asked Questions
What is Amphastar Pharmaceuticals' stock symbol?
Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH."
How were Amphastar Pharmaceuticals' earnings last quarter?
Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) posted its quarterly earnings results on Wednesday, August, 7th. The company reported $0.08 EPS for the quarter, topping the consensus estimate of $0.03 by $0.05. The firm had revenue of $79 million for the quarter, compared to the consensus estimate of $78.90 million. Amphastar Pharmaceuticals had a net margin of 16.33% and a return on equity of 5.52%. The business's revenue was up 11.3% compared to the same quarter last year. During the same period last year, the firm posted $0.03 earnings per share. View Amphastar Pharmaceuticals' Earnings History.
When is Amphastar Pharmaceuticals' next earnings date?
What price target have analysts set for AMPH?
4 analysts have issued 12-month price objectives for Amphastar Pharmaceuticals' shares. Their forecasts range from $22.20 to $29.00. On average, they expect Amphastar Pharmaceuticals' share price to reach $25.05 in the next twelve months. This suggests a possible upside of 26.7% from the stock's current price. View Analyst Price Targets for Amphastar Pharmaceuticals.
What is the consensus analysts' recommendation for Amphastar Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amphastar Pharmaceuticals.
Has Amphastar Pharmaceuticals been receiving favorable news coverage?
News headlines about AMPH stock have been trending negative on Monday, InfoTrie reports. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Amphastar Pharmaceuticals earned a news impact score of -2.6 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Amphastar Pharmaceuticals.
Are investors shorting Amphastar Pharmaceuticals?
Amphastar Pharmaceuticals saw a increase in short interest during the month of September. As of September 15th, there was short interest totalling 1,990,000 shares, an increase of 16.4% from the August 15th total of 1,710,000 shares. Based on an average trading volume of 220,300 shares, the short-interest ratio is currently 9.0 days. Approximately 5.6% of the shares of the stock are sold short. View Amphastar Pharmaceuticals' Current Options Chain.
Who are some of Amphastar Pharmaceuticals' key competitors?
Some companies that are related to Amphastar Pharmaceuticals include GW Pharmaceuticals PLC- (GWPH), United Therapeutics (UTHR), Blueprint Medicines (BPMC), FibroGen (FGEN), Evotec (EVTCY), Arrowhead Pharmaceuticals (ARWR), Mirati Therapeutics (MRTX), Allakos (ALLK), Taro Pharmaceutical Industries (TARO), Nektar Therapeutics (NKTR), Global Blood Therapeutics (GBT), Alkermes (ALKS), Emergent Biosolutions (EBS), Reata Pharmaceuticals (RETA) and Genmab A/S (GMAB).
What other stocks do shareholders of Amphastar Pharmaceuticals own?
Who are Amphastar Pharmaceuticals' key executives?
Amphastar Pharmaceuticals' management team includes the folowing people:
- Dr. Ziping Luo, Chairman, Chief Scientist & COO (Age 69)
- Dr. Yongfeng Zhang, CEO, Chief Science Officer & Director (Age 72)
- Mr. Jason B. Shandell, Pres, Gen. Counsel & Director (Age 45)
- Mr. William J. Peters, CFO, Treasurer & Sr. VP of Fin. (Age 51)
- Mr. Jacob Liawatidewi M.B.A., Sr. VP of Corp. Admin. Center, Sales and Marketing & Corp. Sec. (Age 45)
Who are Amphastar Pharmaceuticals' major shareholders?
Amphastar Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include State of Alaska Department of Revenue (0.06%). Company insiders that own Amphastar Pharmaceuticals stock include Diane G Gerst, Floyd F Petersen, Howard Lee, Jack Y Zhang, Jason B Shandell, Michael A Zasloff, Physics & Chemistry La Applied, Richard K Prins, Richard Koo, Rong Zhou, Stephen B Shohet, William J Peters and Yakob Liawatidewi. View Institutional Ownership Trends for Amphastar Pharmaceuticals.
Which institutional investors are buying Amphastar Pharmaceuticals stock?
How do I buy shares of Amphastar Pharmaceuticals?
Shares of AMPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Amphastar Pharmaceuticals' stock price today?
One share of AMPH stock can currently be purchased for approximately $19.77.
How big of a company is Amphastar Pharmaceuticals?
Amphastar Pharmaceuticals has a market capitalization of $933.74 million and generates $294.67 million in revenue each year. The company earns $-5,740,000.00 in net income (profit) each year or $0.21 on an earnings per share basis. Amphastar Pharmaceuticals employs 2,078 workers across the globe.View Additional Information About Amphastar Pharmaceuticals.
What is Amphastar Pharmaceuticals' official website?
How can I contact Amphastar Pharmaceuticals?
Amphastar Pharmaceuticals' mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The company can be reached via phone at 909-980-9484 or via email at [email protected]
MarketBeat Community Rating for Amphastar Pharmaceuticals (NASDAQ AMPH)
| Community Ranking: | | 2.8 out of 5 ( ) |
| Outperform Votes: | | 310 (Thanks for Voting!) |
| Underperform Votes: | | 248 (Thanks for Voting!) |
| Total Votes: | | 558 |
